InflaRx Announces Participation in September Investor Conferences

InflaRx (Nasdaq: IFRX) announced its participation in two investor conferences in September 2026 in New York.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

InflaRx (Nasdaq: IFRX) announced its participation in two investor conferences in September 2026 in New York.

At the Cantor Global Healthcare Conference 2026, the company will join a fireside chat on September 9, 2026 at 3:20 PM ET and hold one-on-one investor meetings the same day. A live and replay link will be made available online.

At the H.C. Wainwright 28th Annual Global Investment Conference, InflaRx will present on September 14, 2026 at 10:00 AM ET and also conduct one-on-one meetings, with registration and replay access provided via an online link.

Argus Aug 20 session 10 alerts

-4.95% close to close 0.8x rel. volume Open Argus

Details

Market move: IFRX -4.95% in the Aug 20 session. September investor conferences

$299.89M Market Cap

On Aug 20, the day this news came out, IFRX closed 4.95% below the previous close. Our momentum scanner recorded 10 alerts for this stock that day.

Data tracked by StockTitan Argus for the Aug 20 session.

Key Figures

Investor conferences: 2 conferences Cantor conference dates: September 9-11, 2026 Cantor fireside chat: September 9 at 3:20 PM ET +2 more

Investor conferences: 2 conferences; September 2026
Cantor conference dates: September 9-11, 2026; New York, NY
Cantor fireside chat: September 9 at 3:20 PM ET; Cantor Global Healthcare Conference 2026
H.C. Wainwright conference dates: September 14-16, 2026; New York, NY
H.C. Wainwright presentation: September 14 at 10:00 AM ET; 28th Annual Global Investment Conference

Historical Context

5 past events · Latest: Aug 06

5 events

Aug 06
2Q26 earnings report

24h Move

-2.8%

Reported improved loss, expanded funding runway, and strategic focus on izicopan.
Jul 30
Earnings date announcement

24h Move

+4.2%

Scheduled second-quarter financial and operating results release for August 6.
Jun 30
AAV strategy update

24h Move

-1.8%

Assessed broader European vasculitis strategy following EMA recommendation on Tavneos.
May 08
Share offering closing

24h Move

-2.6%

Closed $150 million underwritten offering of 75 million ordinary shares.
May 06
Share offering pricing

24h Move

+26.9%

Priced 75 million ordinary shares at $2.00 per share.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

complement system, c5a, c5ar, pk/pd, +1 more

5 terms

complement system medical

"pioneering anti-inflammatory therapeutics by targeting the complement system"

The complement system is a set of proteins in the blood that act together like a security alarm and cleanup crew for the body’s immune system: they detect threats, tag invaders for removal, and help destroy harmful cells. Investors should care because drugs or diagnostics that target or measure this system can affect treatment effectiveness, safety profiles, and market potential for therapies in immune, inflammatory, and rare disease areas.

c5a medical

"C5a is a powerful inflammatory mediator involved in the progression"

C5a is a small protein produced by the immune system that acts like an alarm bell, signaling and attracting immune cells to sites of infection or injury and triggering inflammation. Investors care because excessive or uncontrolled C5a activity is linked to many inflammatory and autoimmune diseases, making it a common target for drugs and diagnostics; treatments that block or measure C5a can affect clinical outcomes, regulatory approval prospects, and commercial value in biotech and pharmaceutical portfolios.

c5ar medical

"its proprietary anti-C5a and anti-C5aR technologies"

C5aR is a protein on the surface of immune cells that senses and responds to a small immune signaling molecule called C5a; when activated it acts like a doorbell that calls immune cells and ramps up inflammation. It matters to investors because drugs that block or modulate this receptor can reduce harmful inflammation in diseases, so clinical trial results, approvals, or setbacks for C5aR-targeting therapies can materially affect a biotech’s value and market prospects.

pk/pd medical

"has shown promising PK/PD characteristics as well as therapeutic potential"

PK/PD stands for pharmacokinetics and pharmacodynamics: PK describes how a drug moves through the body — how it is absorbed, distributed, broken down and eliminated — while PD describes the drug’s effects on the body and how those effects change with dose. For investors, strong PK/PD data help predict whether a drug can be dosed safely and effectively, shape clinical trial success, regulatory approval chances and commercial potential, much like knowing both delivery speed and the strength of a message before choosing a shipping method.

monoclonal antibody medical

"a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

08/20/2026 - 07:30 AM

Jena, Germany, Aug. 20, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in two investor conferences in September 2026. Details are as follows:

Cantor Global Healthcare Conference 2026
September 9 - 11, 2026 in New York, NY
Fireside chat on September 9^th at 3:20 PM ET

InflaRx will also conduct one-on-one investor meetings on September 9^th. A link to view the fireside chat live stream and its replay will become available here in the coming days.

H.C. Wainwright 28^th Annual Global Investment Conference
September 14 - 16, 2026 in New York, NY
Presentation on September 14^th at 10:00 AM ET

InflaRx will also conduct one-on-one investor meetings on September 14^th. A link to register for the presentation live stream and its replay is available here.

About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The Company is developing izicopan for the treatment of ANCA-associated vasculitis and additional renal diseases. InflaRx also has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.

InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. Follow InflaRx on LinkedIn. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).

Contacts:

InflaRx N.V.	MC Services AG
Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de	Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk Factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will InflaRx (NASDAQ: IFRX) participate in the Cantor Global Healthcare Conference 2026?

InflaRx will participate in the Cantor Global Healthcare Conference 2026 from September 9-11, 2026 in New York. According to InflaRx, a fireside chat is scheduled for September 9 at 3:20 PM ET, alongside one-on-one investor meetings that same day.

What is the date and time of InflaRx's presentation at the H.C. Wainwright 28th Annual Global Investment Conference 2026?

InflaRx will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 at 10:00 AM ET. According to InflaRx, the conference runs from September 14-16, 2026 in New York, with additional one-on-one investor meetings on September 14.

How can investors access InflaRx's (IFRX) fireside chat and presentation webcasts in September 2026?

Investors can access the InflaRx fireside chat and presentation via online live streams and replays. According to InflaRx, links for the Cantor fireside chat will be provided shortly, while registration and replay links for the H.C. Wainwright presentation are already available online.

Will InflaRx hold one-on-one investor meetings at the September 2026 conferences?

Yes, InflaRx plans to hold one-on-one investor meetings at both investor conferences. According to InflaRx, meetings are scheduled for September 9, 2026 at the Cantor Global Healthcare Conference and September 14, 2026 at the H.C. Wainwright Global Investment Conference in New York.

What does InflaRx (IFRX) focus on in its biopharmaceutical programs mentioned with these conferences?

InflaRx focuses on developing anti-inflammatory therapeutics targeting complement factor C5a and its receptor C5aR. According to InflaRx, its lead program izicopan is being developed for ANCA-associated vasculitis and renal diseases, while vilobelimab is an anti-C5a monoclonal antibody studied in multiple clinical trials.

InflaRx Announces Participation in September Investor Conferences

Rhea-AI Summary